ReachMD

ReachMD CME

Your professional development is critical to the care of your patients. Stay on top of the latest treatments and information with ReachMD's CME activities. Our topics span cardiology, diabetes, oncology, cardiology, women's health and more. And our CME library is continuously growing, every quarter.

Určitě navštivte web podcastu a podpořte jeho tvůrce: reachmd.com

Autor

ReachMD

Kategorie

Science

Web podcastu

reachmd.com

Nejnovější epizoda

20. říj 2026

Kde poslouchat?

Podcasty v aplikaci Replaio Radio Už brzy

Podcasty míří do aplikace už brzy. Nainstaluj si ji teď a jako první uvidíš úplně nový pohled na podcasty

Stáhnout z Google Play Nainstaluj zdarma Android 10 mil.+ stažení · hodnocení 4,7+ iOS už brzy

Epizody

Case Consult: Adverse Effect Monitoring, Management, and Mitigation During Targeted Therapy for BRAF-Mutant mCRC 31.03.2025

CME credits: 1.00 Valid until: 02-12-2026 Claim your CME credit at https://reachmd.com/programs/cme/case-consult-adverse-effect-monitoring-management-and-mitigation-during-targeted-therapy-for-braf-mutant-mcrc/33134/ This series provides expert perspectives on the management of metastatic colorectal cancer (mCRC), with a focus on the timing and methodology of molecular testing, targeted treatment...

Proactive Adverse Effect Management in mCRC: Improving Tolerability to Optimize Patient Outcomes 31.03.2025

CME credits: 1.00 Valid until: 02-12-2026 Claim your CME credit at https://reachmd.com/programs/cme/ProactiveAdverseEffectManagementinmCRCImprovingTolerabilitytoOptimizePatientOutcomes/32945/ This series provides expert perspectives on the management of metastatic colorectal cancer (mCRC), with a focus on the timing and methodology of molecular testing, targeted treatment combinations for BRAF-mut...

Defining the Standard of Care and Optimal Sequencing in BRAF-Mutant mCRC: Second Line and Beyond 31.03.2025

CME credits: 1.00 Valid until: 02-12-2026 Claim your CME credit at https://reachmd.com/programs/cme/DefiningtheStandardofCareandOptimalSequencinginBRAFMutantmCRcSecondLineandBeyond/32944/ This series provides expert perspectives on the management of metastatic colorectal cancer (mCRC), with a focus on the timing and methodology of molecular testing, targeted treatment combinations for BRAF-mutant...

From Guidelines to Practice: First-Line Treatment Choices in mCRC 31.03.2025

CME credits: 1.00 Valid until: 02-12-2026 Claim your CME credit at https://reachmd.com/programs/cme/from-guidelines-to-practice-first-line-treatment-choices-in-mcrc/32943/ This series provides expert perspectives on the management of metastatic colorectal cancer (mCRC), with a focus on the timing and methodology of molecular testing, targeted treatment combinations for BRAF-mutant mCRC, and the ma...

Mutational Testing in mCRC: Methods and Data Driving Treatment Selection 31.03.2025

CME credits: 1.00 Valid until: 02-12-2026 Claim your CME credit at https://reachmd.com/programs/cme/MutationalTestinginmCRcMethodsandDataDrivingTreatmentSelection/32942/ This series provides expert perspectives on the management of metastatic colorectal cancer (mCRC), with a focus on the timing and methodology of molecular testing, targeted treatment combinations for BRAF-mutant mCRC, and the mana...

Key Patient Counseling Issues Surrounding FNAIT and Its Risk in Subsequent Pregnancies 31.01.2025

CME credits: 1.00 Valid until: 30-04-2027 Claim your CME credit at https://reachmd.com/programs/cme/key-patient-counseling-issues-surrounding-fnait-and-its-risk-in-subsequent-pregnancies/32283/ Fetal and neonatal alloimmune thrombocytopenia (FNAIT) can lead to substantial medical challenges for the mother, fetus, and neonate. Diagnosis is often difficult without low platelet counts or frank bleedi...

Nipocalimab: An FcRn Inhibitor and Its Role in Treating HDFN 31.01.2025

CME credits: 1.00 Valid until: 30-04-2027 Claim your CME credit at https://reachmd.com/programs/cme/nipocalimab-an-fcrn-inhibitor-and-its-role-in-treating-hdfn/32282/ Fetal and neonatal alloimmune thrombocytopenia (FNAIT) can lead to substantial medical challenges for the mother, fetus, and neonate. Diagnosis is often difficult without low platelet counts or frank bleeding. But a mother’s risk for...

Neonatal FcRn Inhibition: A New Pathway for Addressing the Alloimmune Disorders of Pregnancy 31.01.2025

CME credits: 1.00 Valid until: 30-04-2027 Claim your CME credit at https://reachmd.com/programs/cme/neonatal-fcrn-inhibition-a-new-pathway-for-addressing-the-alloimmune-disorders-of-pregnancy/32281/ Fetal and neonatal alloimmune thrombocytopenia (FNAIT) can lead to substantial medical challenges for the mother, fetus, and neonate. Diagnosis is often difficult without low platelet counts or frank b...

Screening for FNAIT: Anticipating HPA-1a Incompatibility 31.01.2025

CME credits: 1.00 Valid until: 30-04-2027 Claim your CME credit at https://reachmd.com/programs/cme/screening-for-fnait-anticipating-hpa-1a-incompatibility/32280/ Fetal and neonatal alloimmune thrombocytopenia (FNAIT) can lead to substantial medical challenges for the mother, fetus, and neonate. Diagnosis is often difficult without low platelet counts or frank bleeding. But a mother’s risk for FNA...

Managing the “Next Pregnancy” in Patients With an FNAIT-Affected First Child 31.01.2025

CME credits: 1.00 Valid until: 30-04-2027 Claim your CME credit at https://reachmd.com/programs/cme/managing-the-next-pregnancy-in-patients-with-an-fnait-affected-first-child/32279/ Fetal and neonatal alloimmune thrombocytopenia (FNAIT) can lead to substantial medical challenges for the mother, fetus, and neonate. Diagnosis is often difficult without low platelet counts or frank bleeding. But a mo...

Current Management Strategies for FNAIT 31.01.2025

CME credits: 1.00 Valid until: 30-04-2027 Claim your CME credit at https://reachmd.com/programs/cme/current-management-strategies-for-fnait/32278/ Fetal and neonatal alloimmune thrombocytopenia (FNAIT) can lead to substantial medical challenges for the mother, fetus, and neonate. Diagnosis is often difficult without low platelet counts or frank bleeding. But a mother’s risk for FNAIT can be assess...

Current Diagnostic Signs, Symptoms, and Lab Tests for FNAIT 31.01.2025

CME credits: 1.00 Valid until: 30-04-2027 Claim your CME credit at https://reachmd.com/programs/cme/current-diagnostic-signs-symptoms-and-lab-tests-for-fnait/32277/ Fetal and neonatal alloimmune thrombocytopenia (FNAIT) can lead to substantial medical challenges for the mother, fetus, and neonate. Diagnosis is often difficult without low platelet counts or frank bleeding. But a mother’s risk for F...

Classification/Suspecting a Diagnosis of FNAIT/NAIT 31.01.2025

CME credits: 1.00 Valid until: 30-04-2027 Claim your CME credit at https://reachmd.com/programs/cme/classificationsuspecting-a-diagnosis-of-fnaitnait/32276/ Fetal and neonatal alloimmune thrombocytopenia (FNAIT) can lead to substantial medical challenges for the mother, fetus, and neonate. Diagnosis is often difficult without low platelet counts or frank bleeding. But a mother’s risk for FNAIT can...

Fetal/Neonatal Alloimmune Thrombocytopenia (FNAIT): The Platelet Equivalent of Rh Disease 31.01.2025

CME credits: 1.00 Valid until: 30-04-2027 Claim your CME credit at https://reachmd.com/programs/cme/fetalneonatal-alloimmune-thrombocytopenia-fnait-the-platelet-equivalent-of-rh-disease/32275/ Fetal and neonatal alloimmune thrombocytopenia (FNAIT) can lead to substantial medical challenges for the mother, fetus, and neonate. Diagnosis is often difficult without low platelet counts or frank bleedin...

The Alloimmune Disorders of Pregnancy 31.01.2025

CME credits: 1.00 Valid until: 30-04-2027 Claim your CME credit at https://reachmd.com/programs/cme/the-alloimmune-disorders-of-pregnancy/32274/ Fetal and neonatal alloimmune thrombocytopenia (FNAIT) can lead to substantial medical challenges for the mother, fetus, and neonate. Diagnosis is often difficult without low platelet counts or frank bleeding. But a mother’s risk for FNAIT can be assessed...

Chairperson's Perspective: Novel Treatments for Newly Diagnosed Ph+ CML-CP: Striking the Balance of Treatment With Patient Goals and QoL 14.01.2025

CME credits: 0.25 Claim your CME credit at https://reachmd.com/programs/cme/chairpersons-perspective-novel-treatments-for-newly-diagnosed-ph-cml-cp-striking-the-balance-of-treatment-with-patient-goals-and-qol/28646/ Although the first-generation tyrosine kinase inhibitors (TKIs) revolutionized the treatment of Ph+ CML-CP, the rate of resistance to these agents is high, and many patients require fu...

Can We Talk? Optimizing Patient Buy-In to the Management of Endometriosis 09.08.2024

CME credits: 1.75 Valid until: 31-12-2026 Claim your CME credit at https://reachmd.com/programs/cme/can-we-talk-optimizing-patient-buy-in-to-the-management-of-endometriosis/26296/ A paradigm change is occurring in the diagnosis and management of endometriosis. This change will help facilitate the earlier diagnosis of endometriosis and promote more widespread use of medical therapy as opposed to su...

Pre- and Postoperative Use of GnRH Antagonists 09.08.2024

CME credits: 1.75 Valid until: 31-12-2026 Claim your CME credit at https://reachmd.com/programs/cme/pre-and-postoperative-use-of-gnrh-antagonists/26295/ A paradigm change is occurring in the diagnosis and management of endometriosis. This change will help facilitate the earlier diagnosis of endometriosis and promote more widespread use of medical therapy as opposed to surgery for many women. Accom...

The Integral Role of GnRH Antagonists in the Management of Endometriosis 09.08.2024

CME credits: 1.75 Valid until: 31-12-2026 Claim your CME credit at https://reachmd.com/programs/cme/the-integral-role-of-gnrh-antagonists-in-the-management-of-endometriosis/26294/ A paradigm change is occurring in the diagnosis and management of endometriosis. This change will help facilitate the earlier diagnosis of endometriosis and promote more widespread use of medical therapy as opposed to su...

Changing the Paradigm in the Management of Endometriosis: Moving Away From “Surgery First” to “Pharmacologic Therapy First” 09.08.2024

CME credits: 1.75 Valid until: 31-12-2026 Claim your CME credit at https://reachmd.com/programs/cme/changing-the-paradigm-in-the-management-of-endometriosis-moving-away-from-surgery-first-to-pharmacologic-therapy-first/26293/ A paradigm change is occurring in the diagnosis and management of endometriosis. This change will help facilitate the earlier diagnosis of endometriosis and promote more wide...

Capturing the Impact of Endometriosis on Health-Related QoL: The Role of Patient Questionnaires 09.08.2024

CME credits: 1.75 Valid until: 31-12-2026 Claim your CME credit at https://reachmd.com/programs/cme/program-name/26292/ A paradigm change is occurring in the diagnosis and management of endometriosis. This change will help facilitate the earlier diagnosis of endometriosis and promote more widespread use of medical therapy as opposed to surgery for many women. Accompanying this change will be a mor...

Early Diagnosis: Its Pivotal Role in Optimizing Outcomes in Patients With Endometriosis – Psychosocial and Physical Consequences 09.08.2024

CME credits: 1.75 Valid until: 31-12-2026 Claim your CME credit at https://reachmd.com/programs/cme/early-diagnosis-its-pivotal-role-in-optimizing-outcomes-in-patients-with-endometriosis-psychosocial-and-physical-consequences/26288/ A paradigm change is occurring in the diagnosis and management of endometriosis. This change will help facilitate the earlier diagnosis of endometriosis and promote mo...

Improving Outcomes and Addressing Racial Disparities in Patients With HR+/HER2- Early Breast Cancer: A Case-Based Learning Lab 30.04.2024

CME credits: 0.25 Claim your CME credit at https://reachmd.com/programs/cme/improving-outcomes-and-addressing-racial-disparities-in-patients-with-hrher2-early-breast-cancer-a-case-based-learning-lab/16199/ The emergence of the cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) has transformed the treatment landscape for patients with hormone receptor positive/human epidermal growth factor receptor 2...

Expert Answers to Common Questions on Response Matters: Transforming the Standard of Care in CML by Mastering Response-Guided Treatment 13.02.2024

CME credits: 0.25 Claim your CME credit at https://reachmd.com/programs/cme/expert-answers-to-common-questions-on-response-matters-transforming-the-standard-of-care-in-cml-by-mastering-response-guided-treatment/15663/ Chronic myeloid leukemia is a myeloproliferative neoplasm characterized by disordered growth of myeloid cells. The hallmark of chronic myeloid leukemia (CML) is an acquired reciproca...

Chairperson’s Perspective: CDK 4/6 Inhibitors: Practice-Changing Implications of Targeted Therapies in HR+/HER2- Breast Cancer 31.12.2023

CME credits: 0.50 Claim your CME credit at https://reachmd.com/programs/cme/chairpersons-perspective-cdk-46-inhibitors-practice-changing-implications-of-targeted-therapies-in-hrher2-breast-cancer/15715/ By 2040, the global breast cancer burden is expected to increase by 40%, resulting in more than 3 million new cases and 1 million deaths per year. Approximately 65% of cases among women less than 5...

Poslouchej podcast ReachMD CME v Replaio

Rádio a podcasty v jedné aplikaci - zdarma a bez registrace. Nainstaluj si ji ještě dnes a nepropásni premiéru

Stáhnout z Google Play

Replaio není vydavatelem podcastů; názvy pořadů, obálky a audio patří jejich autorům a šíří se přes veřejné RSS kanály